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Key points 49 
Question: What are the clinical and demographic factors underlying the severity of 50 
palmoplantar pustulosis (PPP)?  51 
Findings: In a multi-centre cross-sectional study of 203 UK cases, we observed that the 52 
palmoplantar pustulosis area and severity index was significantly higher in females 53 
compared to males (9.6 vs 4.0) and in current smokers vs former and never-smokers (10.7 vs 54 
7 vs 2.2). Both trends were replicated in an independently ascertained, Northern European 55 
cohort (n=159).  56 
Meaning: These findings suggest that smoking cessation interventions may be beneficial in 57 
PPP, so that their impact should be investigated in clinical studies. 58 
 59 
  60 
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Abstract 61 
Importance: While palmoplantar pustulosis (PPP) can have a profound impact on quality of 62 
life, the factors underlying disease severity have not been studied. 63 
Objective: To define the factors associated with PPP severity. 64 
Design: We undertook an observational, cross-sectional study of two cohorts. A UK dataset 65 
was recruited through the APRICOT clinical trial (2016-2019) and its sister research study 66 
PLUM (2016-2020). A Northern European cohort was independently ascertained by the 67 
European Rare And Severe Psoriasis Expert Network (2013-2017).  68 
Settings: Patients were recruited in secondary or tertiary dermatology referral centres. 69 
Participants: The UK and Northern European cohort included 203 and 193 cases, 70 
respectively. All were or European descent. PPP was diagnosed by dermatologists, based on 71 
clinical examination and/or published consensus criteria.  72 
Main outcomes and measures: Demographics, comorbidities, smoking status, Palmoplantar 73 
Pustulosis Area Severity Index (PPPASI) or Physician Global Assessment (PGA).     74 
Results: Among the 203 UK patients (43 males, 160 females; median age of onset [IQR] 48 75 
[38-59] years), the PPPASI was inversely correlated with age of onset (r=-0.18, P=0.014). 76 
Similarly, in the 159 Northern European cases that were eligible for inclusion in this analysis 77 
(25 males, 134 females ; median age of onset [IQR] 45 [34-53.3] years), the median [IQR] 78 
age of onset was lower in individuals with moderate-to-severe PGA compared to those with 79 
mild-to-clear PGA 41 [30.5-52] vs 46.5 [35-55], P=0.043).  80 
In the UK sample, the median [IQR] PPPASI was higher in females than males (9.6 [3.0-16.2] 81 
vs 4.0 [1.0-11.7], P=0.0096). Likewise, moderate-to-severe PPP was more prevalent among 82 
Northern European females compared to males 57 of 134 [43%] vs 5 of 25 [20%], P=0.026). 83 
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In the UK cohort, the median PPPASI [IQR] was elevated in current smokers compared to ex- 84 
and non-smokers (10.7 [4.2-17.5] vs 7 [2.0-14.4] vs 2.2 [1-6], P=0.003). Comparable 85 
differences were observed in the Northern European dataset, as the prevalence of 86 
moderate-to-severe PPP was higher in former/current smokers compared to non-smokers 87 
(51 of 130 [39%] vs 6 of 24 [25%], P=0.14). 88 
Conclusions and relevance: PPP severity is associated with early-onset disease, female sex 89 
and smoking status. Thus, smoking cessation intervention might be beneficial.  90 
  91 
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INTRODUCTION 92 
Palmoplantar pustulosis (PPP) is an uncommon pustular eruption affecting the palms and/or 93 
the soles. It is observed in approximately 1:2,000 individuals of European descent and 1:800 94 
East Asians1. The disease typically manifests in adulthood, with a median age of onset >45 95 
reported in most studies2. PPP shows a very marked sex bias, as females account for 60-90% 96 
of affected individuals2,3. It is also characterised by a very strong association with cigarette 97 
smoking, with up to 90% of patients self-identifying as smokers at the time of diagnosis2,4-6. 98 
The disease manifests with the eruption of sterile, neutrophil-filled pustules on the palms 99 
and soles. The lesions, which can occur on a background of normal or inflamed skin, are 100 
persistent (>3 months), painful and disabling. They can be accompanied by fissures, pruritus 101 
and a burning sensation7. Co-morbidities are also common, as affected individuals are at 102 
increased risk of psoriasis vulgaris (PsV), psoriatic arthritis and autoimmune thyroid 103 
disease8. 104 
While PPP can have a profound impact on quality of life, the factors underlying variable 105 
disease severity have not been investigated. In fact, the rarity of the condition has hindered 106 
the ascertainment and characterisation of adequately powered datasets. In this context, the 107 
objective of our study was two-fold: i) to evaluate the features of PPP in two independent 108 
patient cohorts; ii) to determine whether PPP severity is influenced by sex and smoking 109 
status, the two most well-established risk factors for the disease. Given that symptoms 110 
typically manifest in adulthood, we also sought to establish whether the presentation of PPP 111 
is more severe in early-onset cases.  112 
 113 
 114 
 115 
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METHODS 116 
Patients 117 
This study was carried out in accordance with the principles of the declaration of Helsinki 118 
and with the approval of the participating institutions’ ethics committees. All patients 119 
granted their informed consent in writing.  120 
The UK resource included 203 unrelated and prospectively ascertained patients. Forty-two 121 
were recruited between 2016 and 2019 through the APRICOT clinical trial (Anakinra in 122 
Pustular psoriasis, Response In a Controlled Trial; EudraCT n. 2015-003600-23). The 123 
remaining 161 were enrolled between 2016 and 2020, through the sister research study 124 
PLUM (Pustular psoriasis, eLucidating Underlying Mechanisms). A total of 23 Dermatology 125 
centres located across the UK were involved in the recruitment. 126 
The Northern-Europe resource included 193 unrelated patients. Affected individuals were 127 
mostly ascertained between 2013 and 2017, through three centres affiliated to the 128 
European Rare And Severe Psoriasis Expert Network (ERASPEN). These were the 129 
Dermatology Departments of the Medical University of Vienna, Austria (n=100), Tartu 130 
University, Estonia (n=57) and University Medical Centre Schleswig-Holstein, Campus Kiel, 131 
Germany (n=31). The remaining 5 patients were recruited outside the main reference 132 
centres, by clinicians who provided individual cases to the ERASPEN Consortium. 133 
Pustular psoriasis was always diagnosed by a dermatologist, based on clinical examination 134 
and/or the ERASPEN consensus criteria7. The observation of sterile, macroscopically visible 135 
pustules on palms or soles was the main inclusion criterion. Conversely, the presence of 136 
pustules restricted to the edges of psoriatic plaques represented an exclusion criterion. 137 
Individuals with concomitant generalised pustular psoriasis or concomitant acrodermatitis 138 
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continua of Hallopeau were also excluded from the study, given that lesions affecting nails 139 
or non-acral skin are deemed incompatible with a diagnosis of PPP9. 140 
Clinical information and key demographics were collated using a standardised case report 141 
form, shared by all centres. In the UK cohort, disease severity was measured using the 142 
Palmoplantar Pustulosis Area Severity Index (PPPASI)10 and the Dermatology Life Quality 143 
Index (DLQI) (eFigure 1 in the Supplement). In the Northern European cohort, patients were 144 
assessed with the Physician Global Assessment (PGA), which has been shown to correlate 145 
with the PPPASI11. The individuals who recorded clinical data and measured disease severity 146 
(reporting dermatologists or trained research nurses) were blinded to the study objectives. 147 
 148 
Statistical analysis 149 
Given that different scoring systems were used in the UK and Northern European cohort, 150 
the two datasets were analysed separately.  151 
The quantitative PPPASI and DLQI measures obtained in the UK cohort were analysed using 152 
the Mann-Whitney test (for binary variables such as sex) or the Kruskal-Wallis test (for 153 
categorical variables such as smoking status). The correlation between PPPASI (or DLQI) and 154 
age of onset was assessed using Spearman's Rank correlation coefficient. To account for the 155 
confounding effects of therapeutic intervention, statistical significance was also confirmed 156 
by regression analysis. PPPASI and DLQI values were normalised (square root 157 
transformation) and analysed vs sex, age of onset or smoking status, using treatment as a 158 
co-variate  159 
To maximise statistical power, the categorical PGA scores recorded in the Northern 160 
European dataset were dichotomised into clear-to-mild (including PGA-0 [clear], PGA-1 161 
[almost clear], PGA-2 [mild]) and moderate-to-severe (including PGA-3 [moderate], PGA-4 162 
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[severe]). The two groups were then compared using Fisher’s exact test. Given that the 163 
purpose of the PGA analysis was to replicate results showing statistical significance in the UK 164 
cohort, P-values were computed based on a one-tailed distribution. As the number of 165 
individuals receiving systemic treatment was relatively small (n=25 from the Medical 166 
University of Vienna and 9 from Tartu University) the confounding effect of therapeutic 167 
intervention was addressed by simply excluding these cases from downstream analyses.  168 
Individuals for whom information on smoking status or age-of-onset was missing (see Table 169 
1 for details) were excluded from the relevant analyses. All statistical tests were 170 
implemented in R (version 3.6.1). P-values<0.05 were considered statistically significant. 171 
 172 
RESULTS  173 
Features of patient cohorts  174 
The features of the UK and Northern European cohorts are summarised in Table 1. All 175 
patients were of European descent. The percentage of females (>75%), median age of onset 176 
(≥45 years) and prevalence of current/former smokers (>80%) were comparable in the two 177 
datasets. Prominent nail involvement was observed in both study populations, with >30% of 178 
patients presenting with at least one of the following: pustules involving the nail apparatus, 179 
subungual hyperkeratosis, permanent nail loss, non-pustular nail dystrophy.  180 
Concurrent PsV was observed in substantial numbers of study participants (66/203 [33%] 181 
British patients and 22/193 [11%] Northern European cases), while psoriatic arthritis was 182 
reported in ~10% of patients from both cohorts (20/203 British cases and 17/193 Northern 183 
European individuals). 184 
Auto-immune thyroid disease was reported in several affected individuals from both 185 
datasets (14/203 [7%] of UK cases and 25/193 (13%) of Northern-European patients). 186 
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Interestingly, the prevalence of obesity (60/150 [40%] in the UK dataset and 51/193 (26%) in 187 
the Northern European sample) was comparable to that observed among British (36%)12, 188 
German (25%)13 and Estonian (21%)13 adults. In keeping with this observation, there was no 189 
correlation between the body mass index of PPP patients and their PPPASI (data not 190 
shown).  191 
While different scoring systems were used in the two cohorts, both included a substantial 192 
proportion of individuals with severe PPP, reflecting ascertainment in hospital settings. 193 
Specifically, 84 of 203 (41%) British patients had a PPPASI>10 and 73/193 (38%) of their 194 
Northern European counterparts had a PGA≥3 (Table 1) 195 
 196 
Factors associated with disease severity 197 
Among UK patients, age of onset was inversely correlated with PPPASI (r=-0.18, P=0.014) 198 
(Figure 1A), although not with DLQI (r=-0.08, P=0.21). Of note, the association with PPPASI 199 
remained significant when the confounding effect of systemic treatment was taken into 200 
account by linear regression (P=0.039) (eTable 1 in the Supplement). In keeping with these 201 
findings, the analysis of the Northern European cohort revealed that the median [IQR] age 202 
of onset was lower in patients with moderate-to-severe PGA compared to those with clear-203 
to-mild PGA (41 [30.5-52] vs 46.5 [35-55], P=0.043) (Figure 1B). Thus, severe PPP appears to 204 
be associated with early disease onset.  205 
In the UK sample, the median PPPASI [IQR] was higher in females compared to males (9.6 206 
[3.0-16.2] vs 4.0 [1.0-11.7], P=0.0096) (Figure 2A). The same applied to the median DLQI 207 
[IQR] (10.5 [4.3-17] vs 4 [1-9], P=8.2 x 10-5) (eFigure 2 in the Supplement). Both associations 208 
were confirmed when the effect of systemic treatment was included in a linear regression 209 
model (P=0.03 for PPPASI, P=0.0001 for DLQI) (eTable 1 in the Supplement). In agreement 210 
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with these observations, the analysis of the Northern European dataset revealed that 211 
moderate-to-severe PPP was more prevalent among females compared to males 57 of 134 212 
[43%] vs 5 of 25 [20%], P=0.026) (Figure 2B). Thus, PPP severity is influenced by the 213 
biological sex of the patient, in both the UK and Northern European study populations.    214 
Among UK patients, the median PPPASI [IQR] was highest in current smokers, intermediate 215 
in former smokers and lowest among non-smokers (10.7 [4.2-17.5] vs 7 [2.0-14.4] vs 2.2 [1-216 
6], P=0.003) (Figure 3A). Comparable findings were obtained when the median DLQI [IQR] 217 
was analysed (10 [4.8-16.3] vs 9 [3-17] vs 5 [1-10.8], P=0.042) (eFigure 3 in the Supplement). 218 
Both associations could be replicated when the effects of systemic treatment were 219 
incorporated into a linear model (P=0.005 for PPPASI, P=0.043 for DLQI) (eTable 1 in the 220 
Supplement). Of note, the percentage of current smokers (18/43 [42%] males and 72/160 221 
[45%] females) and former smokers (19/43 [44%] and 69/160 [43%] females) was 222 
comparable in the two sexes. Moreover, multivariable regression modelling found no 223 
evidence that the effect of smoking differed by gender (data not shown). 224 
While the analysis of the smaller Northern European dataset did not yield statistically 225 
significant results, we observed a similar trend towards increased disease severity in 226 
smokers. In fact, moderate-to-severe PPP was more frequent among current/former 227 
smokers than non-smokers (51 of 130 [39%] vs 6 of 24 [25%], P=0.14) (Figure 3B). 228 
 229 
DISCUSSION 230 
To the best of our knowledge, this is the first systematic study of the factors associated with 231 
PPP severity. It builds on previous work from our network, which enabled the definition of 232 
consensus diagnostic criteria for PPP7 and demonstrated that the disease is genetically 233 
different from other forms of pustular psoriasis2. 234 
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Our investigation confirms key epidemiological features of PPP, such as the late age of onset 235 
and marked sex bias (male to female ratios were >1:3.5 in both cohorts). PsV concurrence, 236 
which is frequently reported in PPP, was also observed in the two datasets. While the 237 
prevalence of PsV in the two cohorts was consistent with published estimates (14-61%)14, 238 
the number of individuals suffering from PPP with PsV was too small for subgroup analyses 239 
and the use of different scoring systems prevented us from merging the UK and Northern 240 
European datasets.  241 
Conversely, the study of the entire resource highlighted aspects of PPP which had not been 242 
systematically investigated before.  243 
We observed nail involvement in approximately a third of affected individuals. Interestingly, 244 
subungual pustulation was reported in a similar fraction of cases in a small UK  study15, 245 
suggesting that nail abnormalities are a consistent feature of PPP. 246 
We also report substantial co-morbidity with psoriatic arthritis, which was present in both 247 
cohorts at a frequency >9%. This markedly exceeds the prevalence of the disease in the 248 
general population (0.1-0.3%)16.  249 
Obesity was relatively uncommon, affecting only a third of all study participants. This 250 
contrasts with findings obtained in PsV, where the association with obesity is well 251 
established17 and up to 42% of individuals with severe disease have a body mass index>3018. 252 
Overall, these findings suggest that PPP is part of the psoriasis spectrum, as the substantial 253 
co-morbidity with PsV and psoriatic arthritis points to shared pathogenic pathways. At the 254 
same time, the distinctive demographics of PPP suggest the involvement of risk factors that 255 
are specific to this particular disease. It is interesting, for instance, that the marked female 256 
bias that characterises PPP is not observed in palmoplantar psoriasis19. Likewise, PsV affects 257 
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both sexes equally20 and occurred with comparable frequency in the male and female 258 
patients examined in this study (data not shown).  259 
Our analysis of PPPASI and PGA scores demonstrated that PPP severity is elevated in 260 
females. Further experimental studies will be required to dissect the causes of this 261 
phenomenon. These may involve genetic modifiers or hormonal imbalances that could be 262 
targeted for disease treatment.  263 
Our study also showed an association between cigarette smoking and disease severity. This 264 
was statistically significant in the UK cohort (P<0.01), where PPPASI values were highest in 265 
smokers, intermediate in former smokers and lowest in non-smokers. This observation 266 
suggests a clinically relevant dosage effect, which could be validated and refined by 267 
analysing pack-year data in further patient resources.  268 
Of note, smoking cessation is sometimes applied to the management of PPP and was found 269 
to be beneficial in a pilot study 21,22. In this context, our findings suggest that the effects of 270 
smoking cessation should be systematically investigated in adequately powered trials. 271 
 272 
Limitations 273 
Our study was exclusively based in secondary and tertiary referral centres, where the 274 
proportion of patients with severe PPP and the burden of co-morbid disease may be higher 275 
than in other settings. Thus, the potential for ascertainment bias limits the generalisability 276 
of our findings. 277 
Different measures of disease severity were used in the UK (DLQI, PPPASI) and Northern 278 
European cohorts (PGA). While all the above scores are widely used in clinical practice, our 279 
results show that the categorical nature of PGA affected the statistical power of the 280 
Northern European cohort and limited our ability to apply correlation-based methods. Thus, 281 
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quantitative measurements such as the PPPASI (or even more sensitive methods such as 282 
machine-learning based pustule counts) should be considered the gold-standard for studies 283 
of PPP severity. 284 
 285 
CONCLUSIONS 286 
Our cross-sectional study underscores the benefits of multi-centre collaborations and 287 
standardised data collection in the analysis of rare skin diseases. It also shows that PPP 288 
symptoms are particularly severe in patients with early onset disease, females and current 289 
smokers. While the latter observation will need to be replicated in further datasets, it 290 
suggests that smoking cessation interventions may benefit the treatment of PPP. 291 
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Table 1. Features of study cohorts 420 
Cohort UK Northern European 
Demographics a   
Sex, F 160/203 (79%) 161/193 (83%) 
Age of onset (years), median (IQR) b 48 (38 - 59)  45 (33 - 54) 
Family history of PsV 65/203 (32%) 33/193 (17%) 
Family history of pustular psoriasis  9/203 (4%) c 10/93 (11%) d 
Smoking status  
Current smokers 90/203 (44%) 124/193 (64%) 
Former smokers 88/203 (43%) 36/193 (19%) 
Never smokers 23/203 (11%) 28/193 (15%) 
Unknown 2/203 (1%) 5/193 (3%) 
Clinical presentation 
Disease duration (years), median (IQR) b 6 (2 – 14) 16 (10 – 20) d 
Nail involvement 65/203 (32%) 64/193 (33%) 
Concurrent PsV 66/203 (33%) 22/193 (11%) 
Concurrent PsA 20/203 (10%) 17/193 (9%) 
Severity  
PPPASI, median (IQR) 8.2 (2.2 – 15.6) - 
21 
 
DLQI, median (IQR) e 10 (3.3 - 16) - 
On systemic treatment f 78/203 (38%) 34/193 (18%) 
PGA  
Clear/Mild (0-2) - 120/193 (62%) 
Moderate/Severe (3-4)  - 73/193 (38%) 
Comorbid disease  
Asthma 25/203 (12%) 5/93 (5%) d 
Depression 31/203 (15%) 28/193 (15%) 
Diabetes  26/203 (13%) 29/193 (15%) 
Hypertension 41/203 (20%) 58/193 (30%) 
Autoimmune thyroid disease 14/203 (7%) 25/193 (13%) 
Obesity g 60/150 (40%) h 51/193 (26%) 
Abbreviations: ACH, Acrodermatitis continua of Hallopeau; DLQI, Dermatology Life Quality Index; F, Female; 421 
GPP, Generalised Pustular Psoriasis; PPPASI, Palmo-plantar Pustular Psoriasis Area Severity Index; PsA, 422 
Psoriatic Arthritis; PsV, Psoriasis Vulgaris; a All study participants were of European descent; b Data not 423 
available for 11 UK and 1 Northern European cases; c one patient had a family history of both PsV and pustular 424 
psoriasis; d Information not available for the 100 cases recruited in Vienna; e Data not available for 8 UK cases; f 425 
On systemic treatment at the time of recruitment or the preceding four weeks; g Body Mass Index > 30; h Data 426 
not available for 53 UK cases. 427 
 428 
  429 
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Figure legends 430 
Figure 1. Relationship between disease severity and age of onset. a: In the UK cohort, the 431 
PPPASI is inversely correlated with age of onset. Regression lines are plotted with their 95% 432 
confidence intervals (grey areas). b: In the Northern European sample, age of onset is 433 
significantly lower among patients with moderate-to-severe disease. Data are presented as 434 
median +/- IQR. *P<0.05 (Mann-Whitney test). 435 
 436 
Figure 2. Disease severity scores in females and males. a: In the UK cohort, PPPPASI scores 437 
are significantly higher in females than males. Data are presented as median +/- IQR. 438 
**P<0.01 (Mann-Whitney test). b: In the Northern European sample, the proportion of 439 
individuals with moderate-to-severe disease is significantly elevated in females compared to 440 
males.  *P<0.05 (Fisher’s Exact test).  441 
 442 
Figure 3. Disease severity scores in current, former and never-smokers a: In the UK cohort, 443 
PPPPASI scores are highest in current smokers, intermediate in former smokers and lowest 444 
in never smokers. Data are presented as median +/- IQR. **P<0.01 (Kruskal-Wallis test). b: 445 
In the Northern European sample, the proportion of individuals with moderate-to-severe 446 
disease is elevated in current/former smokers compared to never smokers.   447 
 448 
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